Research Nester Logo.jpg
Optic Neuritis Treatment Market revenue to hit USD 450 Million by 2035, says Research Nester
27 sept. 2023 07h00 HE | Research Nester
New York, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The global optic neuritis treatment market size is slated to expand at ~ 5% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD...
GMILogo_Vertical-Gradient.png
Diabetic Footwear Market to hit USD 11.9 billion by 2032, says Global Market Insights Inc.
27 août 2023 21h15 HE | Global Market Insights Inc.
Selbyville, Delaware, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Diabetic Footwear Market size will be USD 11.9 billion by 2032. The diabetes footwear market is experiencing substantial expansion due to...
Back Pain & Joint Center of Texas Logo.png
Back Pain & Joint Center of Texas Introduces New Neuropathy Treatments
30 juin 2023 09h00 HE | Back Pain & Joint Center of Texas
Conroe, Texas, June 30, 2023 (GLOBE NEWSWIRE) -- Back Pain & Joint Center of Texas is delighted to announce that new neuropathy treatments are now available. The clinic has the expertise to help...
ST. PETE MEDICAL GROUP
Over 20 Million Suffer From Peripheral Neuropathy, St. Pete Medical Group Aims to Help
14 déc. 2022 12h30 HE | St. Pete Medical Group
ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live. Dr. Alex Spinoso announced their mission...
Dr. Biz Boom
Dr Biz Boom Opens Its Doors in Clearwater, Florida
14 févr. 2022 13h28 HE | Dr. Biz Boom
CLEARWATER, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- After watching her Father suffer for years with Neuropathy while hearing countless Doctors say there was nothing they could do except give him...
Broadway Vascular Logo
Broadway Vascular Opens New Vascular Clinic in San Antonio
19 oct. 2021 09h00 HE | Broadway Vascular
SAN ANTONIO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Broadway Vascular is the new vascular specialist in San Antonio focused on minimally invasive, non-surgical procedures to keep patients out of the...
neurometrix_rgb.jpg
NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Randomized Controlled Trial
15 juin 2021 09h00 HE | NeuroMetrix, Inc.
WOBURN, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to...
neurometrix_rgb.jpg
NeuroMetrix Reports Q1 2021 Financial Results
22 avr. 2021 07h00 HE | NeuroMetrix, Inc.
WOBURN, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in...
neurometrix_rgb.jpg
NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity
01 sept. 2020 13h00 HE | NeuroMetrix, Inc.
WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of...
UPDATE: ECOFIBRE LIMITED – Ananda Health products used in first clinical trial on hemp-derived CBD to treat chemotherapy-induced peripheral neuropathy
23 juil. 2020 08h00 HE | Ecofibre
Georgetown, Kentucky, July 23, 2020 (GLOBE NEWSWIRE) -- Ecofibre Limited (Ecofibre, Company) (ASX:EOF, OTC-NASDAQ Intl Designation: EOFBF) is pleased to announce that the Lankenau Institute for...